Abstract 38P
Background
CD47 and SIRPα (signal-regulatory protein) are tumor biomarkers of innate immunity, expressed on cancer cells and tumor associated macrophages (TAMs); their interaction provides a “don’t eat me” signal that impairs phagocytosis. The relationship between CD47/SIRPα expression and BC aggressiveness has been investigated, however, its prognostic role is not clarified. With these premises, we have assessed the distribution and the possible prognostic value of CD47/SIRPα expression in early BC.
Methods
To verify our hypothesis, we first used in silico data from GOBO and GEPIA, two publicly available datasets: GOBO is a public repository containing microarray data (Affymetrix U133A) from 1881 early BC patients, with a median follow up of 120 months. GEPIA is a web server for analysing RNA expression data of tumours and normal samples from the TCGA and the GTEx projects, by a standard processing pipeline. Immunohistochemical (IHC) analyses were retrospectively performed on formalin-fixed paraffin embedded tissue (FFPE) samples in a cohort of 105 BC patients referred to our institution. The association between CD47 and SIRPα expression levels and outcome was evaluated using the χ2 test. Disease free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier life table method.
Results
In silico data showed that CD47 and SIRPα are preferentially expressed in triple negative (TN) BC, as compared to other BC subtypes (p< 0.0001). CD47 upregulation is associated to a worse OS only in Luminal A BC (GOBO p<0.001, n= 189 patients). By IHC analysis in our retrospective series, CD47 was overexpressed in 80% of TNBC and in 56% of Luminal BC samples. Of note, SIRPα was expressed in 20% of TAMs and in 50% of TN BC samples.
Conclusions
Biomarkers of innate immunity are represented but differently expressed in the different BC subtypes; IHC analyses are ongoing to consolidate this result and to assess their prognostic role in our patient cohort. Final analyses will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - Proteinuria in patients treated with ramcirumab increases the risk of renal dysfunction
Presenter: Kenta Hayashino
Session: e-Poster Display Session
350P - Rheumatologic immune related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy: A Western Australia experience
Presenter: Azim Khan
Session: e-Poster Display Session
351P - Valvular heart diseases in patients treated for breast cancer
Presenter: Ekaterina Kushnareva
Session: e-Poster Display Session
352P - Reproductive system disorders following chemotherapy in patients with breast cancer in Yogyakarta, Indonesia
Presenter: Irfan Haris
Session: e-Poster Display Session
353P - Survey for geriatric assessment in practising oncologists in India
Presenter: Vikas Talreja
Session: e-Poster Display Session
354P - Knowledge, perception, and attitude of oncology-related healthcare providers on complementary and alternative medicine (CAM)
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
355P - Impact of comorbidities and rurality on treatment commencement, completion and outcomes, and health related quality of life, for geriatric oncology patients: Preliminary findings from a regional Australian study
Presenter: Mathew George
Session: e-Poster Display Session
357P - Comparison between immunotherapy and chemotherapy as neoadjuvant setting in resectable non-small cell lung cancer: A systematic review and meta-analysis of prospective trials
Presenter: Chao Zhang
Session: e-Poster Display Session
358P - Adjuvant tyrosine kinase inhibitors in non-squamous non-small cell lung cancer with EGFR driver mutations: An updated meta-analysis of randomized trials
Presenter: Joanmarie Balolong-Garcia
Session: e-Poster Display Session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session